59.6% of Gilenya patients achieve NEDA in study

Gilenya, or Fingolimod, is the first approved oral disease modifying drug for MS.

59.6% of Gilenya patients achieve NEDA in study

Postby MSUK » Thu May 04, 2017 2:22 am

Novartis has announced the results of a phase IV multiple sclerosis (MS) clinical outcomes and MRI study in the US. It confirmed the effectiveness of Gilenya (fingolimod) in a real-world setting, supporting previous findings from phase III trials...Read more - http://www.ms-uk.org/75-gilenya-patients-achieve-neda-study-040517
MS-UK - http://www.ms-uk.org/
User avatar
MSUK
Family Elder
 
Posts: 2869
Joined: Wed Oct 14, 2009 2:00 pm

Advertisement

Return to Gilenya

 


  • Related topics
    Replies
    Views
    Last post

Who is online

Users browsing this forum: No registered users


Contact us | Terms of Service